Targeted knockdown of Bcl2 in tumor cells using a synthetic TRAIL 3'-UTR microRNA.
Targeting tumor-related overexpression of anti-apoptotic Bcl2 protein by RNAi has been suggested as a potential treatment for cancer. However, the stability of RNAi and its delivery are still major obstacles to the clinical testing of Bcl2 RNAi. Here, we explore a novel strategy of expressing a synthetic Bcl2 microRNA (smRNA) in the 3' untranslated region (UTR) of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), an apoptosis-inducing protein without apparent toxic effects in normal cells. TRAIL was specifically expressed from the human telomerase reverse transcriptase promoter (pTRT) that is active in many human tumors. Using this approach, we demonstrated that pTRT drove the tumor-specific expression of Bcl2 smRNA, which was processed by the host RNAi machinery and silenced endogenous Bcl2 expression in tumor cells. Bcl2 smRNA induced tumor cell apoptosis by activating caspase-3 and led to significant sensitization of tumor cells to TRAIL-induced apoptosis, while normal cells were spared. We also showed that the combined therapy of TRAIL-induced apoptosis and Bcl2 downregulation was superior to the mono-therapy of TRAIL or Bcl2 smRNA alone. This study proves a general paradigm for cancer therapy by using 3' UTR microRNA technology.
Zhang
Jianjun
J
Department of Biochemistry and Molecular Biology, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China.
Huang
Shenglin
S
Zhang
He
H
Wang
Haibo
H
Guo
Haiyan
H
Qian
Guanxiang
G
Fan
Xianqun
X
Lu
Jian
J
Hoffman
Andrew R
AR
Hu
Ji-Fan
JF
Ge
Shengfang
S
D020413:3' Untranslated Regions / Q000235:genetics*; D017209:Apoptosis; D045744:Cell Line, Tumor; D006801:Humans; D035683:MicroRNAs / Q000627:therapeutic use*; D009369:Neoplasms / Q000628:therapy*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000037:antagonists & inhibitors* / Q000235:genetics; D034622:RNA Interference; D053221:TNF-Related Apoptosis-Inducing Ligand / Q000235:genetics*
D020413:3' Untranslated Regions; D035683:MicroRNAs; D019253:Proto-Oncogene Proteins c-bcl-2; D053221:TNF-Related Apoptosis-Inducing Ligand; C505653:TNFSF10 protein, human
Cell. 2002 Jan 25;108(2):153-64
11832206
Cell Death Differ. 2004 Aug;11(8):915-23
15118763
Mol Ther. 2009 Jan;17(1):57-64
19018252
Cancer Cell. 2002 Sep;2(3):243-7
12242156
Clin Cancer Res. 2004 Nov 15;10(22):7721-6
15570006
Cancer Res. 1994 Jun 15;54(12):3253-9
8205548
Med Hypotheses. 2007;69(3):537-40
17363184
Nat Rev Cancer. 2002 Sep;2(9):647-56
12209154
Invest New Drugs. 2008 Apr;26(2):193-4
18060598
Semin Hematol. 1997 Oct;34(4 Suppl 5):9-19
9408956
Cancer Gene Ther. 2004 May;11(5):309-16
15031723
Nat Rev Drug Discov. 2002 Feb;1(2):111-21
12120092
Science. 1998 Aug 28;281(5381):1322-6
9735050
Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3627-32
15738415
Life Sci. 2008 Jun 6;82(23-24):1154-61
18485417
Genes Dev. 2003 Apr 15;17(8):991-1008
12672692
Hematol Oncol. 2002 Jun;20(2):63-74
12111869
Curr Biol. 2002 Apr 30;12(9):735-9
12007417
Crit Rev Oncol Hematol. 2002 Jan;41(1):57-77
11796232
Cell Mol Neurobiol. 2006 Jul-Aug;26(4-6):425-38
16710755
Int J Cancer. 2004 Jan 1;108(1):71-7
14618618
Oncology (Williston Park). 2003 Sep;17(9):1244-6, 1251-3, 1258
14569852
J Biol Chem. 1996 Jul 26;271(30):18253-62
8663390
Am J Dermatopathol. 1995 Feb;17(1):7-11
7695015
Br J Cancer. 2004 Jul 5;91(1):171-7
15173860
Science. 2004 Apr 23;304(5670):594-6
15105502
Cell. 1994 Aug 26;78(4):539-42
8069905
Blood. 1993 Jun 1;81(11):3091-6
7684624
J Clin Invest. 1999 Jul;104(2):155-62
10411544
Genome Res. 2004 Oct;14(10A):1902-10
15364901
Hum Immunol. 2005 Mar;66(3):274-84
15784465
Biochim Biophys Acta. 2004 Mar 1;1644(2-3):229-49
14996506
EMBO J. 2006 Nov 15;25(22):5329-38
17082775
Clin Cancer Res. 2004 Jun 1;10(11):3667-77
15173073
J Biol Chem. 1997 Aug 15;272(33):20715-20
9252392
Nat Rev Drug Discov. 2008 Dec;7(12):1001-12
18989337
Nat Rev Cancer. 2005 Nov;5(11):876-85
16239906
Apoptosis. 2001 Jun;6(3):191-7
11388668
Cancer Gene Ther. 2002 Feb;9(2):164-72
11857034
Cancer Gene Ther. 2003 Jul;10(7):540-8
12833134
Curr Opin Investig Drugs. 2001 Apr;2(4):574-80
11566020
Proc Natl Acad Sci U S A. 2002 Nov 12;99(23):14849-54
12403821
J Clin Oncol. 2008 Feb 20;26(6):870-6
18281659
Biochim Biophys Acta. 1999 Dec 10;1489(1):97-106
10807000
Cell. 2000 Jan 7;100(1):57-70
10647931
Cancer Res. 1992 Dec 15;52(24):6940-4
1458483
Mol Cell. 2004 Dec 22;16(6):861-5
15610730
Acta Pharmacol Sin. 2006 Feb;27(2):242-8
16412276
Immunity. 1995 Dec;3(6):673-82
8777713
Oligonucleotides. 2003;13(5):393-400
15000830
Nucleic Acids Res. 2006 Apr 13;34(7):e53
16614444